Boxer Capital, LLC - 23 Jan 2024 Form 4 Insider Report for Mirati Therapeutics, Inc.

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
25 Jan 2024, 16:32:24 UTC
Prior SEC filing
17 Oct 2023
Next SEC filing
08 Feb 2024
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Aaron I. Davis, Chief Executive Officer, Boxer Capital, LLC

Key filing fact

Boxer Capital, LLC filed Form 4 for Mirati Therapeutics, Inc. on 25 Jan 2024.

Key facts

  • This page summarizes Boxer Capital, LLC's Form 4 filing for Mirati Therapeutics, Inc..
  • 8 reported transactions and 3 derivative rows are listed below.
  • Accepted by SEC: 25 Jan 2024, 16:32.

Change

  • Previous filing in this sequence was filed on 17 Oct 2023.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MRTX transaction

Common Stock

Disposed to Issuer

Transaction value
Shares
-287,866
Change %
-100%
Price
Shares after
0
Date
23 Jan 2024
Ownership
See Footnote
Footnotes
F1, F2
MRTX transaction

Common Stock

Disposed to Issuer

Transaction value
Shares
-3,201,440
Change %
-100%
Price
Shares after
0
Date
23 Jan 2024
Ownership
Direct
Footnotes
F1, F3
MRTX transaction

Common Stock

Disposed to Issuer

Transaction value
Shares
-203,754
Change %
-100%
Price
Shares after
0
Date
23 Jan 2024
Ownership
See Footnote
Footnotes
F1, F4
MRTX transaction

Common Stock

Disposed to Issuer

Transaction value
Shares
-3,135,966
Change %
-100%
Price
Shares after
0
Date
23 Jan 2024
Ownership
See Footnote
Footnotes
F1, F5
MRTX transaction

Common Stock

Disposed to Issuer

Transaction value
Shares
-30,518
Change %
-100%
Price
Shares after
0
Date
23 Jan 2024
Ownership
See Footnote
Footnotes
F1, F6

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MRTX transaction Derivative

Warrant (right to purchase)

Disposed to Issuer

Transaction value
Shares
-332,809
Change %
-100%
Price
Shares after
0
Date
23 Jan 2024
Ownership
Direct
Underlying class
Common Stock
Underlying amount
332,809
Exercise price
$0.001000
Footnotes
F3, F7, F8
MRTX transaction Derivative

Warrant (right to purchase)

Disposed to Issuer

Transaction value
Shares
-3,578,036
Change %
-100%
Price
Shares after
0
Date
23 Jan 2024
Ownership
See Footnote
Underlying class
Common Stock
Underlying amount
3,578,036
Exercise price
$0.001000
Footnotes
F5, F7, F8
MRTX transaction Derivative

Warrant (right to purchase)

Disposed to Issuer

Transaction value
Shares
-1,413,475
Change %
-100%
Price
Shares after
0
Date
23 Jan 2024
Ownership
See Footnote
Underlying class
Common Stock
Underlying amount
1,413,475
Exercise price
$0.001000
Footnotes
F5, F7, F8
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 8 footnotes

Footnote F1

On January 23, 2024, Mirati Therapeutics, Inc. (the "Company") filed a Form 8-K with the SEC announcing the consummation of a transaction in which the Company became a wholly owned subsidiary of Bristol-Myers Squibb Company, as described in greater detail therein (the "Merger"). As described in that 8-K, upon the effective time (the "Effective Time") of the Merger each share of Company common stock, par value $0.001 per share, of the Company ("Common Stock") (with certain exceptions) was automatically converted into the right to receive (i) cash in an amount equal to $58.00 subject to applicable withholding tax and (ii) one contingent value right (a "CVR") representing the right to receive $12.00 in cash, without interest and subject to any applicable tax withholding upon achievement of a specified milestone is achieved (as further explained in the Form 8-K) (the consideration contemplated by (i) and (ii), together, the "Merger Consideration").

Footnote F2

These securities are owned directly by MVA Investors, LLC ("MVA Investors"). Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each reporting person other than MVA Investors disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.

Footnote F3

These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. ("Boxer Management") is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Management. Each of Messrs. Fuglesang, Dissanayake and Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.

Footnote F4

These securities are owned directly by Lockend Five, LLC, a limited liability company owned soley by Mr. Dissanayake. Each reporting person other than Lockend Five, LLC and Mr. Dissanayake disclaims beneficial ownership of these securities.

Footnote F5

These securities are owned directly by Braslyn Ltd., which is owned by a revocable trust established by Mr. Lewis for the benefit of members of his immediate family. Each reporting person other than Braslyn Ltd. and Mr. Lewis disclaims beneficial ownership of these securities.

Footnote F6

These securities are owned directly by Mr. Fuglesang. Each reporting person other than Mr. Fuglesang disclaims beneficial ownership of these securities.

Footnote F7

By virtue of the Merger, each then unexpired and unexercised issued and outstanding warrant to purchase shares of Common Stock issued by or on behalf of the Company (each, a "Company Warrant") that was outstanding as of immediately prior to the Effective Time was converted into the right to receive, upon exercise of such Company Warrant, the same Merger Consideration as the holder would have been entitled to receive following the Effective Time if such holder had been, immediately prior to the Effective Time, the holder of the number of shares of Company common stock then issuable upon exercise in full of such Company Warrant without regard to any limitations on exercise contained therein.

Footnote F8

These Company Warrants do not have an expiration date and are not exercisable to the extent that, following exercise, the holder of such Company Warrant and its affiliates would beneficially own more than 19.99% of the Common Stock.

SEC remarks

The reporting persons may be deemed members of a group that beneficially owned more than 10% of the outstanding shares of Company Common Stock prior to the Effective Time.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .